Cervical cancer screening traditionally relies on the Pap smear and HPV-DNA tests. While effective, these methods are fraught with challenges, including variability in human interpretation, false ...
Illuccix is approved in Europe for PSMA-positive lesion detection in prostate cancer, following prior approvals in the US, Australia, and Canada. The phase 3 VISION trial showed 177Lu-PSMA-617 plus ...